Each vial is securely packaged to maintain peptide integrity during transit and storage
Neither were published and Pliva was so excited about the results it abandoned the drug entirely One Phase I safety and pharmacokinetics trial of oral BPC-157, registered in 2015, that has no public results and appears to have been withdrawn or abandoned Three small and nonrandomized uncontrolled pilot studies from a single for-profit clinic in Florida, which included a 16-patient knee-pain chart review, a 12-woman interstitial cystitis study, and a small intravenous safety study One legitimate entry: a registered Phase 2 trial of BPC-157 for acute hamstring strain
Standard dosing Daily dose: 300-600mcg per day Injection frequency: Once daily, preferably in the morning on an empty stomach Administration route: Subcutaneous injection Most users start at 300mcg to assess tolerance, then increase to 500-600mcg if the lower dose is well-tolerated but results are modest
BPC-157 Targeted Injury & Gut Support Starting at $300/vial Promotes site-specific soft tissue repair and supports gut health
Scientists suggest that the BPC157 can be effective to cellular repair by growth factors, but the majority of studies are still in their infancy
